path’s intradermal delivery research projects · 2019. 2. 26. · rabies intradermal study • 2...

PATH’s Intradermal Delivery Research Projects

Intradermal Immunization Meeting - Mérieux Foundation Annecy, Les Pensières April 7-9, 2008

PATH Intradermal Delivery Projects

• Introduction to PATH

• Intradermal Delivery Projects

• Elderly Influenza Intradermal Study (Seattle VA Hospital – Dr. Ru-Chien Chi)

• Microneedle Feasibility Project

• Rabies Intradermal Study

• Needle-Free Injector Project

PATH’s Mission Statement

Our mission is to improve the health of people around the world by advancing

technologies, strengthening health systems and encouraging healthy

behaviors.

PATH’s Global Presence

� > 525 employees� 29 offices, 18 countries

Programs in more than 65 countries.Over 700 staff worldwide

Sources and Uses of FundsSources of revenue – 2007

Source: 2007 budget numbers

PATH’s Program Areas

• Maternal and Child Health and Nutrition

• Reproductive Health

• Health Technologies

• Emerging and Epidemic Diseases

• Vaccines and Immunizations

Microneedle Feasibility Project

• 2 year project (2008 – 2009) Health Innovation Portfolio

• Builds upon 2007 PATH Microneedle Landscape Analysis

• Objectives:

• Determine initial technical feasibility of microneedledelivery for certain vaccines

• Evolve the economic value proposition for microneedles in developing country immunization contexts

• Identify the areas for which basic research needs to be further pursued

Feasibility Project Research

• Aluminum adjuvant vaccine

• Aluminum hydroxide and aluminum phosphate – hollow microneedle

• Plasmid DNA vaccine (HSV 2)

• University of Washington – coated microneedle

• Malaria sporozoite vaccine

• Sanaria / Naval Medical Research Center –hollow microneedle and jet injector

Feasibility Project Status

• Drafting study designs and protocols

• Evaluating microneedle technology platforms

• Connecting with developers to ascertain interest

• Establishing contracts with research groups and collaborators

• Value proposition work initiated

Rabies Intradermal Study

• 2 year project (2008 – 2009) - Health Innovation Portfolio

• Objectives:

• Identify and qualify appropriate microneedle delivery devices or other technologies to facilitate intradermal delivery of rabies vaccine

• Generate necessary pre-clinical data, including immunogenicity data for identified devices

• Facilitate the manufacture of clinical grade prototypes for use in a Phase I clinical trial (to be conducted in India);

• Quantify the value proposition for public health buyers, technology suppliers, and vaccine manufacturers;

• Prepare the groundwork for commercialization, policy, and procurement mechanisms needed for developing a functional market

Rabies Intradermal Project Status

• Preparing technology evaluation protocols and agreements with collaborators

• Connecting with developers to ascertain interest in project participation

• Value proposition work initiated

Needle Free Injector (NFI) Project

• 4 year project (2007 – 2011)

• Funded by the Bill and Melinda Gates Foundation

• PATH Technology Solutions program

• Intradermal delivery component to project

• NFI = Disposable Cartridge/Syringe Jet Injector

http://www.path.org/news/pr080326-dcji.php

NFI Benefits

• Needle-free (safety)

• Compatible with current vaccine vial format (single or multi dose)

• Does not require vaccine reformulation

• Able to deliver ID, SC and IM injections

• Ease of use

NFI Project Objectives

Key Question: Are NFIs appropriate and suitable for developing-country immunization programs?

• Generate clinical, regulatory, and program-use data critical to advance not only a particular NFI design but the entire field of NFI technologies.

• Evaluate the clinical and program feasibility of intradermal delivery of select vaccines of importance to global public health programs in developing countries

• Advance the potential of NFIs appropriate for developing country use by assisting developers in optimizing their product designs, obtaining regulatory approval, planning for scalable production, and facilitating early-adopter markets.

Project Activities

• EPI vaccine bridging studies

• ID clinical trials

• Device regulatory approval (USA / EU / ANVISA)

• Pilot introduction study (Brazil)

• WHO pre-qualification

Scientific Advisory Group

• Comprised of experts who will provide technical, scientific, program and regulatory advice and recommendations for NFI project.

• The advisory group will play a crucial role in the review of:

• NFI design information (pre-clinical, clinical, technical performance)

• Vaccine study designs, protocols and data (ID, SC, IM)

• Confirmation of regulatory strategy

EPI Vaccine Bridging Studies

• Planned cooperation with Brazil National Program for Immunization

• Demonstrate target immune response – comparison with needle and syringe delivery

• EPI ‘set’ of vaccines (SC / IM)

ID Clinical Trials

• Systematic literature review and analysis of previous ID vaccine studies

• Support completion of WHO Oman IPV and CDC DR influenza studies

• Current candidate vaccines (final list in process)

• IPV

• Hepatitis A

• Yellow Fever

• BCG

Device Regulatory Approval

• ID, SC, IM

• FDA / EU / ANVISA

• Device clearance –intended use and general indication for use

Pilot Introduction Study in Brazil

• Cooperation with Brazil NPI

• Immunization clinic pilot use

• Deliver immunization program vaccines

• Multiple sites / locations

• Cost modeling – verify assumptions / variables

• HCW / community acceptability

• Program impact and sustainability

WHO Pre-Qualification

• Support WHO PQS standard development for NFIs (Performance, Quality, and Safety)

• Device third party testing (WHO PQS requirement)

• Data submission to WHO TLAC (Technology and Logistics Advisory Committee) for policy recommendation

NFI Project Status

• Working to finalize timelines and research agenda

• Project partners, agreements, vaccine selection, study designs

• Drafting global regulatory strategy

• Establishing Scientific Advisory Group

Darin ZehrungTechnical OfficerPATH1455 NW Leary WaySeattle, WA 98107dzehrung@path.org206.285.3500

www.path.org